CDC activity of antibodies is evaluable in vivo in the BRGS xenogeneic model. (A) Experimental scheme of this experiment. Raji cells were injected into mice via the tail vein. Ten days after the injection, either rituximab or control IgG2a antibody (200 μg each) was injected IP daily for 1 week. (B) Frequencies of human CD45⁺ Raji cells in the BM of BRGS and NOD-RG mice with or without rituximab injection. A significant reduction of Raji cells was found only in BRGS mice injected with rituximab. (C) Representative FACS plots of the BM cells of BRGS and NOD-RG mice after injection of rituximab or control IgG.